Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20245770 | 0.79 | POLB (0.37) | POLBL3MBTL1MEN1KMT2AIDO1 | |
| SCHEMBL21961917 | 0.78 | POLB (0.39) | POLBL3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL20253619 | 0.74 | TSHR (0.32) | POLBL3MBTL1MEN1KMT2AIDO1 | |
| SCHEMBL24137720 | 0.72 | ALDH1A1 (0.41) | POLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL757258 | 0.72 | — | — | |
| SCHEMBL2121481 | 0.72 | — | — | |
| SCHEMBL3519499 | 0.71 | POLB (0.50) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL18028241 | 0.71 | KDM4E (0.31) | POLBMEN1KMT2AKDM4EMAPT | |
| SCHEMBL24517074 | 0.71 | LMNA (0.32) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL20245656 | 0.70 | POLB (0.32) | POLBL3MBTL1IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403445-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES | CORNELL UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| US-20210403445-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES | CORNELL UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| WO-2020102816-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES | CORNELL UNIVERSITY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403445-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES | LTC4S, LSS, CYCS | POLB 1440/4885L3MBTL1 1369/4885MEN1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.